Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In partnership with the Wellcome Innovations Flagship Programme, MORU launched its Critical Care Asia Network project with its first investigators’ meeting on 19-20 Aug in Bangkok. The project will establish an Asian ICU network across 42 ICUs in nine countries and implement a setting-adapted electronic registry.

Critical care workshop attendees

Using the registry as well as qualitative methods, this project will evaluate the quality of critical care within the network, which will then lead into locally-led quality improvement interventions aiming to improve ICU performance and patient outcomes.

Building on methodology developed by our partners in Sri Lanka, Pakistan and India, the electronic registry will provide epidemiological data and map processes of care, involving caregivers and patients and family members. This will be complemented by qualitative evaluations of care processes, with the aim to empower healthcare teams to identify targets for improvement. Quality improvement interventions and research will be driven by priorities set by the network collaborators. The project works in close collaboration with the Flagship project lead by the OUCRU team on developing new low-cost technologies for ICUs in low/middle income countries. The network will also provide a platform for clinical trials planned for the next phase of the project. Follow the project on Twitter, as well via Rashan’s Twitter handle.

Above photo, collaborators at the Bangkok meeting (front row, from left): Dr Khamsay Detleuxay, Dr Nguyen Thien Binh, Dr Lakshmi Rangananthan, Dr Sophie Yacoub, Dr Rebecca Inglis, Dr Gyan Kayastha, Dr Mavuto Mukaka, Dr Victoria Adewole, Dr Louise Thwaites; (middle row): Dr Nguyen Thanh Nguyen , Dr Dong Phu Khiem, Dilanthi Gamage, Dr Lam Minh Yen, Dr Kathleen Thomas, Dr Bui Thi Hanh Duyen,  Dr Duong Bich Thuy, Dr Madiha Hashmi, Prof Ramani Moonesinghe, Dr Rozina Sultana, Abi Beane, Dr Syed Muhammad Muneeb Ali; (back row): Dr Arshad Taqi, Dr Dinh Minh Duc, Dr Rashan Haniffa, Dr Will Schilling, Ishara Udayanga, Prof. Marcus Schultz, Dr Swagata Tripathy, Prof Arjen M. Dondorp, Dr Muhammad Hayat, Dr Diptesh Aryal. Absent: Dr Steve Harris, Dr Bharath Kumar, Dr Jorge Salluh, Dr Meghan Lever, Dr Chris Pell, Dr Tamilarasu Kadhiravan, Dr Chairat Permpikul, Dr Ratapum Champunot, Dr Gentle Shrestha, Dr Rajyabardhan Pattnaik, Prof Guy Thwaites and Prof Yoell Lubell.

­- With thanks to Abi Beane for text and Jan Ariyalikit for photos

Similar stories

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.